GO
| HSI1 | 25,760.73 | -334.32 | 164.36B |
| HSCEI1 | 9,028.55 | -154.10 | 57.99B |
| Back Zoom + Zoom - Block Traded | |
|
2025-12-03 15:31:44 GIANT BIOGENE (02367.HK) announced on Tuesday (3rd) a plan to repurchase no more than 104 million shares (10% of issued shares) and communicate with the capital market regarding strategies for product matrix expansion, brand operation, and channel development by 2026, according to CICC's research report. CICC viewed the repurchase as a sign of GIANT BIOGENE management's confidence. Meanwhile, the company maintained solid R&D capabilities, brand recognition, and team cohesion. It could improve its operations with product structure optimization, timely operational strategy tweaks, and the increased volume of its second curve medical aesthetics business. The broker was upbeat about its mid-to-long term growth as a leader in recombinant collagen. CICC kept an Outperform rating on GIANT BIOGENE but cut its target price by 20% to HKD56. ~ AAStocks Financial News Web Site: www.aastocks.com | |